Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

Data Compilation
#PharmaFlow

Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

Stock Recap
#PipelineProspector

Valproic Acid

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

69 API Suppliers, 36 USDMF, 10 CEP/COS, 3 JDMF, 8 EU WC, 9 KDMF, 15 NDC API, 36 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

FINISHED DOSAGE FORMULATIONS

267 FDF Dossiers, 110 FDA Orange Book, 57 Europe, 17 Canada, 30 Australia, 17 South Africa, 36 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SYRUP;ORAL - 250MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 125MG VALPROIC ACID, TABLET, DELAYED RELEASE;ORAL - EQ 250MG VALPROIC ACID, TABLET, DELAYED RELEASE;ORAL - EQ 500MG VALPROIC ACID, CAPSULE, DELAYED REL PELLETS;ORAL - EQ 125MG VALPROIC ACID, TABLET, EXTENDED RELEASE;ORAL - EQ 250MG VALPROIC ACID, TABLET, EXTENDED RELEASE;ORAL - EQ 500MG VALPROIC ACID

RELATED EXCIPIENT COMPANIES

12 Evonik, 3 Rochem International Inc, 20 SPI Pharma, 17 DKSH, 1 Pharm-RX Chemical, 8 Faran Shimi Pharmaceutical, 11 Boai NKY Pharmaceuticals Ltd, 6 Gangwal Healthcare, 9 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 4 ACG Worldwide, 8 Actylis, 1 Aeon Procare, 3 Alcedo Pharmachem, 10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Avesta Pharma, 38 BASF, 2 Clariant, 18 Corel Pharma Chem, 6 DFE Pharma, 3 Doshion Polyscience, 2 Finar, 13 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 16 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 34 Kerry, 4 Kima Chemical, 6 Lonza Capsugel, 18 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 5 Novo Excipients, 4 Pharmatrans-Sanaq, 8 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 27 Roquette, 14 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 3 The Dow Chemical Company, 2 Ulanqab Kema New Material, 3 Valens Pharmachem, 4 Vasa Pharmachem, 2 Vertellus

EXCIPIENTS BY APPLICATIONS

103 Fillers, Diluents & Binders, 89 Coating Systems & Additives, 51 Controlled & Modified Release, 45 Disintegrants & Superdisintegrants, 44 Thickeners and Stabilizers, 43 Solubilizers, 43 Direct Compression, 38 Taste Masking, 35 Granulation, 31 Film Formers & Plasticizers, 26 Topical, 22 Lubricants & Glidants, 21 Parenteral, 19 Chewable & Orodispersible Aids, 17 Co-Processed Excipients, 13 Rheology Modifiers, 11 Emulsifying Agents, 9 Empty Capsules, 9 API Stability Enhancers, 6 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules

DIGITAL CONTENT

61 News #PharmaBuzz

61 News #PharmaBuzz

GLOBAL SALES INFORMATION

6 US Medicaid Prescriptions, 91 Regulatory FDF Prices, 5 Annual Reports

MARKET PLACE

26 APIs, 16 FDF Dossiers

REF. STANDARDS & IMPURITIES

2 EDQM, 3 USP, 5 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Labeler	NDC Package Code	Non Proprietary Name	Start Marketing Date	End Marketing Date	Category Code	Dosage Form (Strength)
28/03/2025	Seqens	France	PCAS FRANCE	49169-1028	DIVALPROEX SODIUM	2010-07-07	2025-12-31	BULK INGREDIENT	POWDER (1kg/kg)
28/03/2025	Dr. Reddy\'s Laboratories	India	Dr.Reddy's Laboratories Limited	55111-875	Divalproex Sodium	2006-10-16	2026-12-31	BULK INGREDIENT	POWDER (1kg/kg)

Valproic Acid

Valproic Acid

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

69 API Suppliers

36 USDMF

10 CEP/COS

3 JDMF

8 EU WC

9 KDMF

15 NDC API

36 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

2 Drugs in Development

FINISHED DOSAGE FORMULATIONS

267 FDF Dossiers

110 FDA Orange Book

57 Europe

17 Canada

30 Australia

17 South Africa

36 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

SYRUP;ORAL - 250MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 125MG VALPROIC ACID

TABLET, DELAYED RELEASE;ORAL - EQ 250MG VALPROIC ACID

TABLET, DELAYED RELEASE;ORAL - EQ 500MG VALPROIC ACID

CAPSULE, DELAYED REL PELLETS;ORAL - EQ 125MG VALPROIC ACID

TABLET, EXTENDED RELEASE;ORAL - EQ 250MG VALPROIC ACID

TABLET, EXTENDED RELEASE;ORAL - EQ 500MG VALPROIC ACID

RELATED EXCIPIENT COMPANIES

12 Evonik

3 Rochem International Inc

20 SPI Pharma

17 DKSH

1 Pharm-RX Chemical

8 Faran Shimi Pharmaceutical

11 Boai NKY Pharmaceuticals Ltd

6 Gangwal Healthcare

9 Nanjing Well Pharmaceutical

2 Pfanstiehl

4 ACG Worldwide

8 Actylis

1 Aeon Procare

3 Alcedo Pharmachem

10 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

1 Avesta Pharma

38 BASF

2 Clariant

18 Corel Pharma Chem

6 DFE Pharma

3 Doshion Polyscience

2 Finar

13 Gangwal Chemicals

1 Huzhou Sunflower Pharmaceutical

16 Ideal Cures Pvt Ltd

5 Ingredion Pharma Solutions

34 Kerry

4 Kima Chemical

6 Lonza Capsugel

18 Microlex e.U

1 Nanjing Bold Chemical

2 Nomisma Healthcare

5 Novo Excipients

4 Pharmatrans-Sanaq

8 Pluviaendo

4 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

2 Qualicaps

27 Roquette

14 Seppic

8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Shijiazhuang Huaxu Pharmaceutical

12 Sigachi Industries

CAPSULE;ORAL - 250MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

SYRUP;ORAL - 250MG/5ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons